Literature DB >> 10464385

Disseminated Langerhans' cell histiocytosis and massive protein-losing enteropathy.

T M Santos-Machado1, L M Cristófani, M T Almeida, P T Maluf, P A Costa, M A Pereira, J L Brito, V Odone-Filho.   

Abstract

Symptomatic involvement of the gastrointestinal (GI) tract as a prominent symptom in Langerhans' cell histiocytosis (LCH) is uncommon, occurring in less than 1 to 5% of all cases, even when the disease is in its disseminated form. Up to now, there have been reports of 18 cases of LCH with GI manifestations, including our 2 cases, with diarrhea (77.7%), protein-losing enteropathy (33.3%) and bloody stool being the most frequent findings. The authors present two patients with severe diarrhea and refractory hypoalbuminemia, and with the protein-losing enteropathy documented by Cr51-labeled albumin studies. A review of the literature indicated that the presence of GI symptoms is often associated with systemic disease as well as with poor prognosis, mainly under 2 years of age. Radioisotopes are useful for documenting protein loss in several diseases with high specificity and sensitivity, and their utilization in the cases reviewed here permitted diagnoses in 6 children, as well as improved therapeutic management.

Entities:  

Mesh:

Year:  1999        PMID: 10464385     DOI: 10.1590/s0100-879x1999000900007

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  2 in total

1.  Intestinal Langerhans cell histiocytosis-like lesion in an adult presented with diverticulitis: a reactive or neoplastic condition?

Authors:  Özgür Mete; Öner Doğan; Yersu Kapran; Deniz Tihan; Yeşim Erbil; Selçuk Ozarmağan
Journal:  Pathol Oncol Res       Date:  2010-10-26       Impact factor: 3.201

2.  Successful treatment with 2-chlorodeoxyadenosine of refractory pediatric Langerhans cell histiocytosis with initial involvement of the gastrointestinal tract.

Authors:  Azusa Mayumi; Toshihiko Imamura; Kenichi Sakamoto; Takeshi Ota; Shinya Osone; Ikuya Usami; Hajime Hosoi
Journal:  Int J Hematol       Date:  2019-07-26       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.